Eli Hazum
Directeur Technique/Scientifique/R&D chez PAINREFORM LTD.
Profil
Eli Hazum is currently the Chief Executive Officer at Regentis Biomaterials Ltd.
He also holds the position of Director & Chief Technology Officer at PainReform Ltd.
Additionally, he is a General Partner, Partner, and CSO at Medica Venture Partners.
In his former roles, Dr. Hazum served as the Chief Executive Officer of Ester Neurosciences Ltd.
and Collgard Biopharmaceuticals Ltd.
He also held the position of Chief Executive Officer at Regentis Biomaterials Ltd.
Furthermore, he worked as the Vice President of Research & Development at Peptor Ltd and as the Head of Receptor Research & Metabolic Diseases at Glaxo, Inc. He started his career as a Principal at Biotechnology General (Israel) Ltd.Dr. Hazum obtained his undergraduate and graduate degrees from Tel-Aviv University.
He earned a doctorate degree from the Weizmann Institute of Science.
Additionally, he holds an MBA from both The University of Lincoln and Humberside University.
Postes actifs de Eli Hazum
| Sociétés | Poste | Début |
|---|---|---|
| PAINREFORM LTD. | Directeur Technique/Scientifique/R&D | 01/04/2018 |
Medica Venture Partners
 Medica Venture Partners Investment ManagersFinance Medica Venture Partners (Medica Venture Partners) is a venture capital firm founded in 1995 by Yuval Binur, Ehud Geller and Jonathan Fleming. The firm is headquartered in Israel. | Directeur Technique/Scientifique/R&D | 01/01/1995 |
Regentis Biomaterials Ltd.
 Regentis Biomaterials Ltd. BiotechnologyHealth Technology Regentis Biomaterials Ltd. engages in the research and development of proprietary hydrogels for local repair of damaged cartilage and bone. Its product is GelrinC. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel. | Directeur Général | 01/01/2021 |
Anciens postes connus de Eli Hazum
| Sociétés | Poste | Fin |
|---|---|---|
Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd. BiotechnologyHealth Technology Regentis Biomaterials Ltd. engages in the research and development of proprietary hydrogels for local repair of damaged cartilage and bone. Its product is GelrinC. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel. | Directeur Général | - |
Biotechnology General (Israel) Ltd.
 Biotechnology General (Israel) Ltd. Pharmaceuticals: MajorHealth Technology Biotechnology General (Israel) Ltd. manufactures and markets pharmaceutical products. Its products include Aminopeptidase B, Euflexxa, Zomacton, BioTropin, and Carboxypeptidase. The firm has operations in Europe, Japan, and the United States. The company was founded in 1980 and is headquartered in Kiryat Malachi, Israel | Corporate Officer/Principal | - |
| Glaxo, Inc. | Corporate Officer/Principal | - |
| Peptor Ltd | Directeur Technique/Scientifique/R&D | - |
Ester Neurosciences Ltd.
 Ester Neurosciences Ltd. Medical SpecialtiesHealth Technology Ester Neurosciences Ltd. engages in the research and development of screening assays. The company was founded on June 17, 1997 and is headquartered in Tel Aviv, Israel. | Directeur Général | - |
Formation de Eli Hazum
| Tel-Aviv University | Graduate Degree |
| Weizmann Institute of Science | Doctorate Degree |
| The University of Lincoln | Masters Business Admin |
| Humberside University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PAINREFORM LTD. | Health Technology |
| Entreprise privées | 7 |
|---|---|
| Peptor Ltd | Health Technology |
Medica Venture Partners
Medica Venture Partners Investment ManagersFinance Medica Venture Partners (Medica Venture Partners) is a venture capital firm founded in 1995 by Yuval Binur, Ehud Geller and Jonathan Fleming. The firm is headquartered in Israel. | Finance |
Ester Neurosciences Ltd.
Ester Neurosciences Ltd. Medical SpecialtiesHealth Technology Ester Neurosciences Ltd. engages in the research and development of screening assays. The company was founded on June 17, 1997 and is headquartered in Tel Aviv, Israel. | Health Technology |
Collgard Biopharmaceuticals Ltd.
 Collgard Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Collgard Biopharmaceuticals, the tissue therapeutics company, is developing drug treatments that target disease progression by directly influencing the tissue regeneration process. Central to Collgard's novel approach is its lead drug candidate, Tempostatin (Halofuginone hydrobromide). Tempostatin is a multi-indication, small-molecule drug candidate that has been identified by the company as influencing a 'master switch' in the body's tissue repair process. As a potent and selective regulator of stromal cell activation, cell migration and excessive collagen type I synthesis, Tempostatin makes it possible to harness and direct the tissue repair process for treating diseases acting at the tissue level. Collgard is developing therapeutic solutions for several clinical indications with significant unmet clinical needs. These solutions are based on highly specific control of the tissue repair process. Current programs target the following indications vascular restenosis, end-organ fibrosis, selected cancers and dermal fibroproliferative disorders. Tempostatin holds exceptional promise based on addressing a fundamental underlying pathological process that is not accessible to other current therapeutic approaches. In developing Tempostatin, Collgard seeks to offer novel therapeutic solutions as well as extend the effectiveness of existing therapies. Founded in 1996, Collgard Biopharmaceuticals is a privately held, clinical stage company, led by a global team of medical and drug development experts based in Atlanta and Tel Aviv. Scientific and clinical collaborators include The Mayo Clinic, the U.S. NCI, the EORTC, and Harvard Medical School. Collgard was founded by Medica Venture Partners. Additional investors include Mayo Medical Ventures, Denali Ventures, Yozma Group, and Comsor. | Health Technology |
| Glaxo, Inc. | |
Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd. BiotechnologyHealth Technology Regentis Biomaterials Ltd. engages in the research and development of proprietary hydrogels for local repair of damaged cartilage and bone. Its product is GelrinC. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel. | Health Technology |
Biotechnology General (Israel) Ltd.
Biotechnology General (Israel) Ltd. Pharmaceuticals: MajorHealth Technology Biotechnology General (Israel) Ltd. manufactures and markets pharmaceutical products. Its products include Aminopeptidase B, Euflexxa, Zomacton, BioTropin, and Carboxypeptidase. The firm has operations in Europe, Japan, and the United States. The company was founded in 1980 and is headquartered in Kiryat Malachi, Israel | Health Technology |
